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There is mounting evidence of impacts of single base substitutions in both somatic and 
inherited genetic diseases.  However, the occurrence of single base mutations in the 
germline and gametes has previously only been by conjecture and assumption.  There is a 
need for understanding the risk of offspring inheriting small intragenic mutations, the 
frequencies at which these mutations are present in germ cells, and the impact that these 
inherited mutations may have son the predisposition to somatic disease during one’s 
lifetime.  The present study attempts to establish baselines of mutational frequencies in 
two well characterized genes in human tissues, and demonstrate the prevalence of 
mutations in two genes, Kristen-ras (KRAS) and TP53 in direct analysis of semen 
specimens.  These two genes play important roles in human disease.  Eleven normal 
human male volunteers’ semen specimens were tested for single base substitutions (SBS). 
A detection sensitivity of one mutant cell in 106 wild type cells was achieved with the aid 
of an ultra-sensitive detection method, which utilizes the combined power of the 
polymerase chain reaction, restriction endonuclease, and ligase chain reaction techniques.  
The first base of the TP53 gene codon 248, 282, 273 and the second base of codon 273 
and the first base of the Kristen-Ras (KRAS) gene codon 12 were studied.  The observed 
mutation prevalence was significantly higher in the first base of the codon 248 of the 
TP53 gene compared to the first base of codon 273 or the first base of codon 282, both 
(both P< 0.006).  Similarly, there was a significant difference between the prevalence of 
the first base of codon 12 of the KRAS gene and the first base of codon 273, or the first 
base of codon 282 (both P< 0.04).  Interestingly, the SBS mutation prevalence was nearly 







TP53 gene (P< 0.006).  The spectra of base substitution mutations observed in this study 
may provide clues to the mutational mechanisms present in human sperm, and may lead 
to the improved risk assessment for genetic counseling.  These data represent the first 
reports of mutational frequencies in the TP53 and KRAS genes in normal human semen 
specimens, and demonstrate that single base mutational frequencies for different genes 










 Despite the advances in molecular biology during the last two decades, such as 
the human genome project, sequence data, and microarray technologies, there are still 
relatively few studies looking at mutations in human sperm.  Microarrays coupled with 
automation have resulted in large-scale experiments and the development of extensive 
databases to handle the enormous amounts of information.  Unfortunately, only limited 
data are available for a database in the mutational frequencies unique to human sperm 
(Wiederkehr et al., 2004).  Traditionally, obstacles to exploring mutations in sperm 
included; the lack of specificity and/or sensitivity when focusing on a single gene or 
region within a single gene, and the labor intensive nature of standard techniques, e.g., 
mouse specific locus (Wilson et al., 1999).  Direct analysis of sperm has been undertaken 
with a number of methods including fluorescence in situ hybridization (Sloter et al., 
2000), hamster-egg method (Brandriff et al., 1990), and flow or laser-scanning cytometry 
(Pasteur et al., 1994; Baumgartner et al., 2001; Cordelli et al., 2005).  However, these 
studies have for the most part, been driven by clinical infertility and the search for gross 
chromosomal abnormalities that may be transmitted through gametes (Rudak et al., 1978; 
Shelby et al., 1993; Hassold et al., 1996; Rubes et al., 2002; Schmidt et al., 2004).   
1.2 Chromosome Aberrations 
Chromosomal aberrations are associated with a wide range of defects, genetic 
diseases, and mortality (Wyrobek et al., 2000).  Chromosomal aberrations have been 
estimated to occur in ~ 0.6% of live-born infants (Hassold et al., 1996; Marchetti and 




may be much higher, since many of these mutations are not compatible with conception, 
implantation, embryogenesis and/or life.  Based on clinically recognized conceptions 
(i.e., pregnancies), approximately 85% make it to birth, with miscarriage occurring in 10-
15% (Lauritsen, 1975; Kalousek et al., 1993; Hassold, 1996).  However, Wilcox et al., 
1988, and Tommerup, 1993, propose that 30-50% of all conceptions do not lead to 
recognized pregnancies.  A significant proportion of the conceptions that do not survive 
to live offspring may be the result of genetic errors, so that only about 50% of all 
conceptions (recognized and unrecognized) survive to birth (Marchetti and Wyrobek, 
2005).  Using the human sperm-hamster oocyte fusion system and more recently a 
multicolor fluorescence in situ hybridization (FISH) assay, it has been shown that 
structural aberrations may be widespread in the sperm of infertile men (Rudak et al., 
1978; Schmidt et al., 2004).  Rubes et al., 2002, utilized FISH techniques to examine 
multiple semen specimens collected from healthy men over a two year period, and 
identified men who consistently produced elevated frequencies of aneuploid sperm.  
Rudak et al. 1978, suggest that chromosomal abnormalities occur at a rate of 5-7% in 
normal sperm from fertile males, which is consistent with the structural chromosomal 
abnormality rate of 5-13% found by Marchetti and Wyrobek, 2005.   
With the mounting evidence of the impact of single base substitution in somatic cells and 
the potential to cause heritable disease in progeny, there is a need for understanding the 
risk of offspring inheriting rare mutations, frequencies at which these mutations are 







1.3 Single-base Substitution Mutations  
 The occurrence of constitutional deletions, insertions, and single base-substitution 
(SBS) mutations is well known in various genetic diseases (i.e., Sickle-cell anemia, 
Retinoblastoma, Neurofibromatosis type 1, Fragile X syndrome, Li-fraumeni syndrome, 
etc.)(Table 1).  However, the determination of the frequency of sperm harboring these 
mutations has been difficult due to technical limitations (sensitivity and/or specificity).  
The frequency of SBS has been widely proposed in the literature as an indicator of 
somatic disease, heritable predisposition to somatic disease, and/or exposure to one or 
more genotoxic agents (Loeb et al., 2003; Wilson et al., 2000; Wilson, 2001).  The 
transmission of de novo SBS mutations, unlike chromosomal aberrations, generally 
results in a viable fetus, but is a major etiological factor in hereditary predisposition to 
disease.  This is seen most notably in the high penetrance of autosomal dominant diseases 
and predisposition to disease caused by SBS mutations such as achondroplasia (FGFR3), 
apert syndrome (FGFR2), multiple endocrine neoplasia type 2 (RET), and retinoblastoma 
(RB) among others (Table 2).   Traditionally, the reported frequencies of germline 
mutations are estimated from the prevalence or incidence of disease in the population.  
Orioli et al., 1986, estimated an Achondroplasia mutation rate of 1.72 to 5.57 x 10-5 per 
gamete per generation (based on birth prevalence of 0.5 to 1.5/10,000).  Thus far, 
Achondroplasia causing mutations appear to be 100% of paternal origin (Tiemann-Boege 
et al., 2002) so that this mutation rate corresponds with the reported frequency of 0.5 to 
1.5 x 10-5 for FGFR3 G1138A mutants present in human sperm (Tiemann-Boege et al., 
2002).  The birth prevalence of Apert syndrome has been reported to be 1.5 x 10-5, which 
predicts the same prevalence of the mutation in sperm (Goriely et al., 2003).  Dryja et al., 




allele in Retinoblastoma.  De novo mutations are reported to account for 20% to 30% of 
the mutations in retinoblastoma and the germ cell mutation rate is estimated to be 9.3 x 
10-6 to 10.9 x 10-6 per generation (Fitzgerald et al., 1983).  These disease associated 
mutation SBS frequencies suggest a sperm SBS mutation frequency of 1 x 10-4 to 1 x 10-5 
mutant sperm per total spermatozoa sampled.   A germ cell p53 mutation rate of 1 x 10-4 
mutant sperm per total spermatozoa sampled, would suggest that disease associated 
mutations potentially leading to a disease prevalence of greater than one in one-hundred 
thousand for the Li-Fraumeni cancer family syndrome.  The actual prevalence of Li-
Fraumeni in the human population is much less than 1 x 10-6 per generation (Bendig et 
al., 2004), which suggests either these estimated mutation rates are inaccurate or an 
opposing biological selection occurs during the processes of conception to birth.   
The research study reported here utilizes direct analyses of human semen samples 
to determine the prevalence of mutations in the Kristen-Ras (KRAS) and TP53 genes, 
both of which have important roles in human disease (i.e. cancer).  The goals of these 
experiments are to establish base-lines of mutational frequencies of two well 
characterized genes in human sperm.  The specific objectives are to determine whether 
SBS mutational frequencies in the TP53 and KRAS genes can be obtained from direct 
analysis of human semen specimens, and to determine whether or not SBS mutational 
frequencies in sperm are similar between activating (KRAS) and de-activating (TP53) 
mutations.   
1.4 Human TP53 and Kristen-Ras (KRAS) Gene 
The tumor suppressor gene TP53 (MIM#191117) encodes a transcription factor with 
multiple anti-proliferative functions activated in response to several forms of cellular 
stress.  
Table 1.  Examples of genetic diseases caused by insertion and deletion mutations. 
 
Disease                        mutation            prevalence            expecteda           gene            Reference(s)     __       
Cri du chat                   deletion             2 x 10-5                     1.0 x 10-5 b         chr-5           Overhauser et al.,  
                             1994  
Fragile X                     CGG repeats      5 x10-5                           FMR 1        Jacobs, 1982 
 
Hemophilia                                       2 x 10-4                 2 x 10- 4                    Factor VIII Soucie et al., 1998 
X –linked                                                (live male births)                           or IX 
 
Hemophilia B              inversion            7.7 x 10-6             3.85 x 10-6 c           “              Green et al., 1999  
  
Huntington                  CAG repeats       4 x 10-6                2 x 10-6 c              HD            Duyao et al., 1993     
              to 6 x 10-6            to 3 x 10-6 c
       
Neurofibromatosis      deletion               2.9 x 10-4              2.5 x 10-4 c           NF1           Lazaro et al., 1996 
(~90%)                    
       
Retinoblastoma          deletion                4.35 x 10-5            1.9 x 10-5 c            “              Sippel et al., 1998 
               to 6.25 x 10-5        to 2.8 x 10-5 c            
 
 “                                deletion             “                     1.3 x 10-5 c            “               Lohmann et al.,  
                                    (~31%)                             1996   
 
 Wilms Tumor            deletion                1 x 10-3                5 x 10-4 c              WT1         Olson et al., 1993    
                                       (children) 
 
 
a expected frequency in sperm calculated from population prevalence and percent due to a paternal mutation 
b paternal genome represents ≤ 10% of the mutation incidence 




Table 2.  Examples of genetic diseases caused by single base substitution mutations. 
 
Disease                   mutation             prevalence             expecteda                 gene            Reference(s)_              _ 
Apert syndrome      1.5 x 10-5              1.5 x 10-5  b                                                            Blank, 1960 
                                  to 6.25 x 10-6      to 6.25 x 10-6 b                          Cohen et al., 1992 
     
 “                              base-                  “                   1 x 10-6 b                  FGFR2      Glaser et al., 2003 
                                substitution   (est.)   
                                755C→G 
                                758C→G 
Achondroplasia       base-                  0.5-1.5 x 10-6       0.5-1.5 x 10-6 b                          Mettler Fraser, 1999    
                                substitution      
 
“                               1138G→A         “                          “              FGFR3       Tiemann-Boege et al.,  
                                      2002 
 
Hemophilia                                         2 x 10-4               2 x 10- 4 c                Factor VII   Soucie et al., 1998 
              (live male births)                              or IX               
                                   X –linked 
  
Hemophilia B         base-                    7.7 x 10-6             3.85 x 10-6c            Factor IX    Giannelli et al., 1992 
                                substitution                X –linked   
 
Retinoblastoma       base-                   4.35 x 10-5            9 x 10-6 d              RB1             Lohmann et al.,1996 
                                substitution         to 6.25 x 10-5       to 1.3 x 10-5 d                                    




a expected frequency in sperm calculated from population prevalence and percent due to a paternal mutation  









c assumed ~50% mutation from paternal genome 
d based on 85% paternal (Dryja et al, 1997) for de novo mutations, and ~25% of prevalence due to de novo  
   mutations (Fitzgerald et al, 1983). 
 
 
The p53 protein promotes apoptosis in response to an accumulation of genetic errors, 
thereby inhibiting the processes that may lead to neoplastic development (Hussain and Harris 
1999; Martin et al., 2002).  Somatic mutation of TP53 is a common occurrence in most human 
cancers, with the vast majority of the mutations being (missense) single base-substitutions 
(Hussain et al., 2003).  A third of the mutations of the TP53 gene occur in “hotspot” codons such 
as 175, 176, 245, 248, 249, 273, and 282 (Wilson et al., 2001; Olivier et al., 2003, Tapp et al., 
2007).  Mutations in other tumor suppressor genes (APC, BRCA1, ATM, and RB1) are mostly 
deletions or insertions (Hussain and Harris, 2006).  These intragenic SBS mutations in the TP53 
gene can lead to a change in one amino acid in the protein.  Tumor derived p53 mutants 
containing a point mutation within the DNA binding domain prevents, or in some cases alters, 
the recognition of p53 binding sites (Yee and Vousden, 2005).  Point mutations that prevent or 
alter the binding sites could be described as “de-activating” the normal functions of the p53 
protein.  Yu et al., 1999, proposed that transcription activation by p53 is essential to its role as a 
tumor suppressor.  Recent studies have suggested that the TP53 mutation may act as an oncogene 
or displaying gain of oncogenic function by altering the expression of associated proteins 
(Glazko et al., 2006; Hussain and Harris, 2006).  TP53 has been described as a “guardian of the 
genome” (Lane, 1992) but if that role is mitigated by inheritance of a mutated copy, the resulting 
effects are poorly understood. 
Germline mutations of p53 have been identified in >70% of families with Li-Fraumeni 
syndrome (LFS; MIM# 151623).  Determining the frequency of TP3 mutations in human sperm 
is crucial to understanding germline mutagenesis as it pertains to susceptibility to disease such as 




The RAS gene family (KRAS, NRAS, and HRAS) encodes highly conserved GTP-
binding proteins and guanosine triphosphatases (GTPases).   Ras proteins act as molecule 
switches, being active when it binds GTP and inactive when it binds GDP (De-Qing et al., 2004; 
Potenza et al., 2005; Kratz et al., 2006).  Activating mutations of the RAS genes cause the 
protein to remain permanently in its active state, which in turn signals a number of effector 
proteins that control many cellular pathways (e.g., transcription and proliferation).  The majority 
of the KRAS gene (MIM#190070) mutations found in codons 12, 13 and 61, are single base 
substitutions which lead to the change of one amino acid in the protein (Bos et al., 1987; De-
Qing et al., 2004).  The RAS genes are the most frequently activated oncogenic family in human 
cancers (Bos, 1989).  Kratz et al., 2006, observed that activating oncogenic mutations in the 
HRAS gene affecting codons 12 or 13 are not detrimental to the developing embryo, when 
present in the germline, whereas oncogenic KRAS mutations affecting these residues appear to 
be embryonically lethal.   Although HRAS and KRAS are structurally similar, they perform 
different roles during embryonic development and KRAS developmental functions cannot be 
mitigated by the HRAS or NRAS (Koera et al., 1997; Kratz et al., 2006).  This hypothesis is 
supported by evidence in KRAS-deficient mice, in which the KRAS deficiency resulted in the 
defect of myocardial cell proliferation and neuronal programmed cell death (Koera et al., 1997). 
Determining the prevalence of Kras mutations in human sperm could suggest whether or 
not this type of mutation is found in sufficient number to have the potential to be inherited, a lack 
of individual with clinical evidence, or if the absent of viable offspring is due solely to the 
suggested lethality in embryogenesis. The objectives of this study are to determine whether or 




analysis of human semen specimens, and whether SBS mutational frequencies in sperm are 
similar between activating (KRAS) and de-activating (TP53) mutations.   
1.5 Disease Causing Mutations in the Human TP53 and Kristen-RAS (KRAS) Genes, 
Somatic vs. Germline Mutations 
 
Both somatic and germline DNA mutations have biological selection barriers for the 
propagation and clonal expansion of genetic errors.  For somatic mutations, selection may be 
based on cell type and tissue specific functions as well as oncogenic processes.  Somatic 
mutations in oncogenes and tumor suppressor genes are rare in normal tissue.  TP53 gene 
mutations are seen mostly in various types of cancers (e.g., head-neck, breast, lung, adenomas, 
sarcoma, etc ((see http://p53.free.fr and www-p53.iarc.fr)), and in tissues exposed to mutagens or 
carcinogen (i.e. lung cancers) (Soussi and Beroud, 2001; Hwang et al., 2003; Szymanska and 
Hainaut, 2003; Glazko et al., 2006).   Although Harvey-Ras and N-Ras gene mutations are found 
in many cancers, mutations in the KRAS gene are typically found in carcinomas of the pancreas, 
lung, colon, and thyroid (Andreyev et al., 1998 and 2001; De-Qing et al., 2004; Mascaux et al., 
2005). 
Heritable germline mutations must be compatible with gamete functions, conception, 
early cleavage, implantation, and embryonic and fetal development. Regardless of the type, 
many mutations ranging from chromosomal aberrations to single base mutations may occur in 
somatic cells but remain exceedingly rare simply because they do not provide for or enhance cell 
division and clonal expansion of the new genotype.  However, any mutation in gametes that does 
not terminally interfere with reproductive and developmental processes is freely propagated and 
present in every cell of the offspring.  Understanding the risk of disease due to DNA mutation 
induction in humans requires clarification of the occurrence and frequencies of mutations and 




has been published on this subject associated with somatic diseases.  Unfortunately, mutation 
spectra and frequencies in the germline have not received the same degree of attention. 
Germline mutations in TP53 are identified in 70% of families with Li–Fraumeni 
syndrome (LFS; MIM# 151623), and 20%-30% of Li-Fraumeni-like (LFL) syndrome (Olivier et 
al., 2002; Wu et al., 2006). The LFS syndrome displays dominant inheritance and confers 
susceptibility to breast carcinoma, soft tissue sarcoma, brain tumors, osteosarcoma, leukemia, 
and adrenocortical cancers (Hisada et al., 1998).   
Recently, germline mutations in the KRAS gene were discovered in patients with Noonan 
and cardio-facio-cutaneous (CFC) syndromes (Kratz et al., 2006).  These syndromes are 
characterized by short, distinct facial anomalies, heart defects, and other abnormalities.  
Moreover, it has been suggested that these particular mutations (V14I and T58I) demonstrated 
unique aspect in the KRAS protein function that offers an explanation as to why the affected 
individuals survived during embryonic development (Kratz et al., 2006).  It must be noted that 
these mutations are adjacent to, but not the typically altered amino acids residues in most cancers 
relating to this gene, such as codons 12, 13, and 61.  
The present work focuses on heritable and nonheritable gene mutations in human sperm.  
As has been discussed, there are inherent differences in the mutational spectrum, mode, action, 
and severity of effects in various tissues.  Therefore we hypothesize that there are differential 
patterns of mutational frequencies, and spectra of mutations in both TP53 and KRAS genes that 
will be present in human sperm.  To test this hypothesis I examined five loci, four codons in the 
TP53 and one codon in the KRAS genes, to determine whether or not SBS mutational 




specimens.  Additionally, I hope to determine whether or not SBS mutational frequencies in 






























The Taq polymerase (Amplitaq Gold) was purchased from Applied Biosystems (Foster 
City, CA).  Msp1, Hph1, and BsaA1 restriction endonucleases, Taq DNA Ligase for the LCR 
amplification, and T4 polynucleotide kinase for end-labeling, were purchased from New England 
Biolabs (Beverly, MA).  [γ- 32P] ATP Redivue was purchased from Amersham/GE Healthcare 
Corporation (Arlington Heights, IL).  Oligonucleotide primers were purchased as custom 
synthesis from BioServe Biotechnologies Ltd (Laurel, MD). 
2.2 Human Semen Specimens 
In collaboration with Dr. Andrew Carlson (Albany Medical College), human semen 
specimens (n=11) were obtained from consenting volunteers.  No personal information, 
including age of the donor, was available due to the format of the consent forms and guidelines 
of Institutional Review Board.  The specimens were completely anonymous.  This study was 
approved by the Human Subjects Institution Review Boards of Albany Medical College (Albany, 
NY) and Louisiana State University (Baton Rouge, LA).  Samples were frozen and kept at -80°C 
until DNA isolation was performed.  In this study, eleven individuals’ samples were analyzed for 
the presence of single base substitution mutations at five different codons in two genes.   
2.3 DNA Isolation 
All sperm DNA’s were isolated after a preparatory step to ensure the removal of superfluous 
materials (i.e. proteins, RNA’s, somatic DNA’s, etc).  Briefly, samples were transferred to 1.5ml 
tubes centrifuged at 4,000 rpm for 15-20 minutes in an Eppendorf centrifuge.  The suspension 




was at the bottom of the tubes.  The samples were kept at room temperature for 15-20 minutes 
then 400 µl grinding buffer was added.  The samples were pelleted by centrifuged for 10 
minutes, and then the solution was decanted and suspended in 50 µl hyaluronidase solution, 
vortexed, centrifuged and incubated at 37oC for 1-1.5 hours.  The samples were suspended in 50 
µl collagenase/dispase/ringers solution and 5 µl DNase (2 units per µl), vortexed, centrifuged 
and incubated at 37oC for 1-1.5 hours.   The samples were decanted, then suspended in 500 µl 
grinding buffer, lysing buffer, and a final incubation in the presence of 20 µl 6.7% β-
mercaptoethanol solution (34µM final concentration) to crack the spermatozoa capsule (Clark 
and Wilson; unpublished protocols).   The vortexed, centrifuged and decanted DNA was isolated 
with a standard proteinase K, chloroform/phenol extraction followed by ethanol precipitation 
(Wilson et al., 2001; Tapp et al., 2007).  DNA concentration was measured on a 
spectrophotometer with ratio 260/280 nm from 1.50 to 1.95.  In case the ratio was not within the 
specified range, re-isolation of the DNA was repeated until the DNA 260/280 nm ratio was 
within the range of 1.5 to 1.95.  
2.4 Multiplex –PCR/ RE/LCR Analysis 
Tables 3 thru 6, contains the primer sequences, annealing temperatures, and product sizes of 
the polymerase chain reaction (PCR)/ restriction-endonuclease digestion (RE)/ Ligase chain 
reaction (LCR) selection and detection procedure for each specified gene site, which have been 
reported by Wilson et al., 1999, 2000;Tapp et al., 2007.  Figure 1, contains a flow chart of the 
PCR and restriction endonuclease selection.  The following is a brief summary of this method; 
sperm DNA samples were subjected to a multiplex mutant enrichment protocol in which three 
PCR amplification steps and two wild-type specific RE digestion steps were performed followed 




Applied Biosystems 9700 Thermal-Cycler (Foster City, CA), in a total reaction volume of 50µl, 
containing 2.5  U AmpliTaq Gold, with supplied buffer, 1.7mM MgCl2, 200mM 
deoxynucleoside triphosphates, and 1 mM of each PCR primer (Table 3).  Restriction 
endonuclease digestion were performed on the PCR product (>5 hours) using Msp1 (> 10U/20µl 
reaction) and BsaA1 (> 10U/20µl reaction) for codons 248 and 273, respectively, and Hph1 (> 
10U/20µl reaction) for codon 12 of the KRAS gene (Table 4).  The third PCR product from the 
PCR/RE selection was analyzed for base substitution mutations using site-specific LCR designs.  
A 30-cycle LCR amplification was then performed using 1µl of the final PCR/RE selection 
product as template.  The LCR amplifications were performed with 10 µl reactions containing ~ 
500,000 c.p.m. of 5’ 32P end-labeled invariant primers, 1 µm of each wild-type or mutant 
discriminating primer (Tables 5 and 6), 4 µg sheared Salmon sperm DNA, and 15 U Taq Ligase 
(New England Biolabs, Beverly, MA) in prepared LCR Buffer (20mM Tris-Hcl (pH) 7.6), 
100mM KCL, 10 mM MgCl2, 1mM EDTA, 10 mM dithiothreitol, 1mM NAD+, and 0.1% Triton 
X-100) (Tapp et al., 2007).  The prevalence of mutant cells (number of mutants per wild-type 
cells) in each sperm sample was determined by PCR/RE selection and LCR analyses utilizing 
decreasing quantities of sperm DNA.  Beginning with 6 µg and decreasing to 3, 0.6, and 0.3 µg 
DNA, and 0 µg (no template control) the detection of mutant in these titrations represents a 
prevalence of 1 x 10-6 (6µg), 2 x 10-6, 1 x 10-5, and 2 x 10-5, respectively. Human tumor cell lines 
SW837 (CCL-235), A549 (CCL-185), Calu 1 (HTB-54), LS180 (CL-187), and SW480 (CCL-
228) were obtained from the American Type Tissue Culture (Rockville, MD) and grown as 
recommended for use as mutant DNA standards according to their known mutations.  Isolated 





Table 3.  PCR and Oligonucleotide template standards for PCR/RE/LCR analyses. 
PCR 
Primers 
Sequence (5’ to 3’) Size 
Hp53 exon 7 
E7A AGGCGCACTGGCCTCATCTTG 21mer 
E7F GACTGTACCACCATCCATACAA 22mer 
E7GR GGCAAGTGTCTCCTGACCTG 20mer 
E7RB GTGTGCAGGGTGGCAAGTGTC 21mer 




E8SR GGGCAGCTCGTGGTGAGG 18mer 
E8R TGGTCTCCTCCACCGCTTCTTG 22mer 
E8S GTGAGCAGGGTAGAGGAGAGCG 22mer 
HKRAS exon 1 codon 12 site 1 and site 2 
E1A  TTGCATTATTTTTATTATAAGGGCGGCTGAAAATG 35mer 






















Figure 1.  Flow chart of PCR and Restriction Endonuclease Selection. 
Modified from Wilson et al., 2001 
 
Table 4.  PCR primers, Restriction Endonucleases, and Annealing Temperatures. 
 




PCR Product size (bp) 
PCR #1   Msp1, BsaA1 and Hph 1 60   
Hp53E7 - Hp53E7R 66 237 bp 
Hp53E8BsaA1 - Hp53E8R 60 184 bp 
HKrasE1A - HKRAS12HphlR4 60 172 bp 
PCR #2  A         Msp1 (only) 65  
Hp53E7A - Hp53E7RB 66 178 bp 
Hp53E8S – Hp53E8R 65 181 bp 
PCR #2  B         BsaA1 and Hph 1 65  
Hp53E8S – Hp53E8R 65 181 bp 
HKRASE1A – HKRASE1FR2 66 166 bp 
PCR #3  A          Msp1 (only) 60  
Hp53E7F – Hp53E7GR 60 118 bp 
Hp53E8S – Hp53E8SR 65 126 bp 
PCR #3  B          BsaA1 and Hph 1 60  
Hp53E8S– Hp53E8SR 65 126 bp 












































LCR Primers Sequence (5’ to 3’) Size 
L2 Hp53c248s1 GGAGGCCCATCCTCACCATC 20 mer 
LR2  Hp53c248s1 GTTCATGCCGCCCATGCAGG 20 mer 
MtHp53c248s1 GL AAAAAAAAATGGGCGGCATGAACG 24 mer 
MtHp53c248s1 AL AAAAAAATGGGCGGCATGAACA 22 mer 
MtHp53c248s1 TL       AAAAATGGGCGGCATGAACT 20 mer 
WtHp53c248s1 L AAATGGGCGGCATGAACC 18 mer 
MtHp53c248s1 GLR AAAAAAAGAGGATGGGCCTCCC 22 mer 
MtHp53c248s1 ALR AAAAAGAGGATGGGCCTCCT 20 mer 
MtHp53c248s1 TLR AAAGAGGATGGGCCTCCA 18 mer 
WtHp53c248s1 LR AGAGGATGGGCCTCCG 16 mer 
L2 Hp53c282s1 GGGGCGAACAGAGGAAGAGAATCTCCG 27 mer 
LR Hp53c282s1 CACAAACACGGACAGGACCCTCTCTG 26 mer 
MtHp53c282s1 GL AAAAAAAAAACTGTCCTGGGAGACGACG 28 mer 
MtHp53c282s1 AL AAAAAAAACTGTCCTGGGAGACGACA 26 mer 
MtHp53c282s1 TL AAAAAACTGTCCTGGGAGACGACT 24 mer 
WtHp53c282s1 L AAAACTGTCCTGGGAGACGACC 22 mer 
MtHp53c282s1 CL2 GCCCGCTTGTCTCCTTCTCTATATTA 26 mer 
MtHp53c282s1 TL2 ACCGCTTGTCTCCTTCTCTTATTA 24 mer 
MtHp53c282s1 AL2 TCCGCTTGTCTCCTTCTCATAT 22 mer 
WtHp53c282s1 LR2 GCCGCTTGTCTCCTTCTCTT 20 mer 
L  Hp53c273s1 GTGTTTGTGCCTGTCCTGGGAGAGA 25 mer 
LR  Hp53c273s1 CCATCTCGCTGCCTTGTCGAAACTCCAT 28 mer 
MtHp53c273s1 GL AAAATAAGACGGAACAGCTTTGAGGTAG 28 mer 
MtHp53c273s1 AL AATAAGACGGAACAGCTTTGAGGTAA 26 mer 
MtHp53c273s1 TL TAAGACGGAACAGCTTTGAGGTAT 24 mer 
WtHp53c273s1 L CGACGGAACAGCTTTGAGGTAC 22 mer 
WtHp53c273s1 LR AAACAGGACAGGCACAAACACG   22 mer 
MtHp53c273s1 TLR AAAAACAGGACAGGCACAAACACA 24 mer 
MtHp53c273s1 ALR AAAAAACCAGGACAGGCACAAACACT    26 mer 
















Table 6. LCR Primers for TP53 codons 273 site 2 and KRAS codon 12 site 1.  
LCR Primers                     Sequence (5’ to 3’) Size 
L  Hp53c273s2 TGTTTGTGCCTGTCCTGGGAGAGAC 25 mer 
LR  Hp53c273s2 CATCTCGCTGCCTTGTCGAAACTCCATG   28 mer 
MtHp53c273s2 CL ATATACGACGGAACAGCTTTGAGGTACC 28 mer 
MtHp53c273s2 AL ATAAATCGGAACAGCTTTGAGGTACA 26 mer 
MtHp53c273s2 TL AAATCGGAACAGCTTTGAGGTACT 24 mer 
WtHp53c273s2 L GACGGAACAGCTTTGAGGTACG 22 mer 
WtHp53c273s2 LR AAACCAGGACAGGCACAAACAC 22 mer 
MtHp53c273s2 TLR AAAAACCAGGACAGGCACAAACAA 24 mer 
MtHp53c273s2 ALR AAAAAAACCAGGACAGGCACAAACAT 26 mer 
MtHp53c273s2 CLR AAAAAAAAACCAGGACAGGCACAAACAG 28 mer 
LR2  HKRASc12s1 GTGACGTAGGCAAGAGTGCAGGTC 24 mer 
MtHKrasc12s1CL AAAAAAAAAAACTTGTGGTAGTTGGAGCTC 30 mer 
MtHKrasc12s1TL AAAAAAAAACTTGTGGTAGTTGGAGCTT 28 mer 
MtHKrasc12s1AL AAAAAAACTTGTGGTAGTTGGAGCTA 26 mer 
WtHKrasc12s1L AAAAACTTGTGGTAGTTGGAGCTG 24 mer 
L3  HKRASc12s1 AGCTCCAACTACCACAAGTTTATATTCAGTC
A 
32 mer 
WtHKrasc12s1LR2 CACTCTTGCCTACGTCACC 19 mer 
MtHKrasc12s1ALR2 AGCACTCTTGCCTACGTCACT 21 mer 
MtHKrasc12s1TLR2 AAAACACTCTTGCCTACGTCACA 23 mer 



























To demonstrate assay sensitivity at one in a million, control mixtures were prepared with 
6 µg genomic DNA and 6 pg of genomic mutant (cell line) DNA.  The purchased Human 
Genomic DNA was checked for mutations at the base sites of interest at the 10-7 sensitivity 
before use in these mutant standard mixtures to insure a negative background.   
Significant differences between semen specimens (n =11) for mutation frequency and 
prevalence were determined by a Chi-squared test for dichotomous variables and the t-test and 
one-way analysis of variance (ANOVA) for continuous variables.  Correlations between 
variables were assessed by pairwise covariance and linear regression methods.  The statistical 




















RESULTS AND DISCUSSION 
 
3.1 General Results 
 
Single-base substitution mutations were found in 13 of 55 (24%) base pair sites tested in 
normal human sperm specimens; per semen specimen one or more mutations were identified in 8 
of 11 (73%)(Table 7).  Overall, TP53 codon 248 mutations (Figure 2) were more frequent (6/11, 
55%) than KRAS codon 12 (4/11, 36 %).  Five specimens were not analyzed for mutants in 
TP53 codon 282 site 1 due to limited sample size and required quantities of DNA.  In a previous 
study, no mutations were observed in 19 specimens of peripheral blood leukocytes for codon 282 
(Yin, Xiuquin and Wilson, VL, unpublished data).  A representative autoradiograph of TP53 
codon 282 site 1 is shown in Figure 3.  Similarly, no mutations were observed in the eleven 
semen specimens for TP53 codon 273 site 1 (Figure 4).  In contrast, three (27%) of the semen 
samples had mutants in TP53 codon 273 site 2 (Figure 5).  Lastly, four of the eleven (36%) 
semen specimens tested where positive for mutants in KRAS codon 12 site 1.  Figure 6, is a 
representative autoradiograph of KRAS codon 273 site 1.  Listed in order decreasing of 
frequency: TP53 codon 248 site 1 (55 %), KRAS codon 12 site 1 (36%), TP53 codon 273 site 2 
(27%), and both TP53 codon 273 site 1 and TP53 codon 282 site 1 (0%). A summation of the 
specific mutation and frequency range (prevalence) found in eleven human semen specimens are 
presented in Table 7.   
There were significant differences in the frequency of mutations between the TP53 and 
KRAS genes, specifically KRAS codon 12 site 1 compared to TP53 codon 282 site 1 and codon 




within the TP53 gene, specifically TP53 codon 248 site 1 compared to TP53 codon 282 site 1 
and TP53 codon 273 site 1 (both were P< 0.006).   
Five samples (45%) harbored more than one mutation identified (all 5 specimens 
harbored 2 single base pair mutations). Specimens S02-365, S03-401, S00-026, S03-241, and 
S03-428 each contained two mutations out of five loci examined.    Three specimens harbored 
only one mutation (S02-054, S03-401, and S03-050), and there were no detectable mutations in 
three specimens (S01-010, S02-063, and S03-398).  Overall, no significant differences in the 
frequency of mutations were found between the eleven specimens (P< 0.49) (Table 7).      Base 
pair transitions were the only type of mutation identified in this study (Table 7).  TP53 codon 
248 site 1 contained only C>T mutations, whereas both TP53 codon 273 site 2 and KRAS codon 
12 site 1 contained only G>A mutations (Table 7).  Table 8, contains a raw data comparison of 
sperm, peripheral blood leukocytes (PBL) and adjacent normal vulvar skin.  Similar base pair 
transition C > T mutations, were observed in both PBL and adjacent normal vulvar skin.  In 
contrast, adjacent normal vulvar skin harbored both G > A, and G > C (transitions and 
transversions) mutations in TP53 codon 273 site 2 and G > A, and G >T mutations in KRAS 
codon 12 site 1 (Table 8).  Interestingly, the SBS mutation frequencies of TP53 were found to be 
higher in sperm than that previously reported for normal tissue (Table 8).  This was due to the 
elevated mutation frequency of the first base of codon 248 in sperm.  The proportion of semen 
specimens providing detectable C > T mutations in TP53 codon 248 was twice that reported for 
circulating peripheral blood leukocytes (PBL) (Wilson et al., 2000), or normal skin (normal 
vulvar skin and fore skin) specimens (Tapp et al., 2007), although the differences are not 




samples was similar to that reported for normal adjacent skin, but higher than that reported for 
normal skin without adjacent cancer. 
3.2  Mutational Spectrum   
 
The spectrum of SBS mutations found in this study of semen specimens was limited to 
only transition mutations.   A similar spectrum of SBS mutations, with the vast majority being C 
> T or G > A transitions, causing human genetic disease has been described by Cooper and 
Krawczak, 1990.  It has been reported that a bias for transitions at CpG sites, such as those seen 
in the first base in TP53 codons 248 and 273 site 1 and 2 (Magewu and Jones, 1994; Drost and 
Lee, 1995; Tapp et al., 2007) may be the result of 5-methyldeoxycytidine deamination.  
Oxidative processes may enhance 5- methyldeoxycytidine deamination, although this reaction 
also occurs spontaneously (Magewu and Jones, 1994). Comparisons of the present work with 
published studies are contained in Table 8.  The proportion of semen specimens proving 
detectable C > T mutations in TP53 codon 248 was twice that reported for normal skin (normal 
vulvar skin and foreskin) specimens (Tapp et al., 2007), or circulating peripheral blood 
leukocytes (PBL) (Wilson et al., 2000), although the differences are not significant.  No 
mutations were detected in sperm in the first base of codon 273 (Table 8), but this finding is 
consistent with the rarity of mutations at this TP53 base site, as reported by Tapp et al., 2007, in 
normal skin adjacent to squamous cell carcinoma.   In contrast to the present spectra results, 
observations in vulvar skin specimens by Tapp et al., 2007, included G > C mutations in the 
second base of codon 273, and G > T mutations in the first base of codon 12 of KRAS.  G > A 
transitions, were the only type of mutations observed in our study of the KRAS gene.  G > A 
transitions, which can occur due to bypass misreplication of unrepaired endogenously produced 
O6 –methylguanine, are one of the most frequent point mutations for all human somatic missense 
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Figure 2.  Representative autoradiograph of TP53 codon 248 site 1 (specimen S00-026). 
PCR blank: negative control during PCR/RE selection with no DNA template (water).  LCR 
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA 
per specimen; 2x10-6:  3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:  
0.3µg of DNA per specimen. Wt:  LCR products from Wild–type DNA strands; A and G:  one 
pmol of each oligomeric standards mutant A and mutant G were included in these analyses as 
positive mutation standard markers (see Table 5 for primer sequences).  A standard 10-6 mixture 
of genomic DNA from the SW837 cell line provided verification of the detection sensitivity of 
the mutant T standard.  Film was exposed for 1 hour.  Reprinted by permission of John Wiley & 
Sons, Inc. 
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Figure 3. Representative autoradiograph of TP53 codon 282 site 1 (specimen S03-401). 
PCR blank: negative control during PCR/RE selection with no DNA template (water).  LCR 
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA 
per specimen; 2x10-6:  3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:  
0.3µg of DNA per specimen. Wt:  LCR products from Wild–type DNA strands; MtT, MtA, and 
MtC:  one pmol of each oligomeric standards mutant T, mutant A, and mutant C were included 
in these analyses as positive mutation standard markers (see Table 5 for primer sequences).  Film 
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Figure 4.  Representative autoradiograph of TP53 codon 273 site 1 (specimen S01-010). 
PCR blank: negative control during PCR/RE selection with no DNA template (water).  LCR 
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA 
per specimen; 2x10-6:  3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:  
0.3µg of DNA per specimen. Wt:  LCR products from Wild–type DNA strands; MtT, MtA, and 
MtC:  one pmol of each oligomeric standards mutant T, mutant A, and mutant C were included 
in these analyses as positive mutation standard markers (see Table 5 for primer sequences).    
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Figure 5.  Representative autoradiograph of TP53 codon 273 site 2 (specimen S03-241).   
PCR blank: negative control during PCR/RE selection with no DNA template (water).  LCR 
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA 
per specimen; 2x10-6:  3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:  
0.3µg of DNA per specimen. Wt:  LCR products from Wild–type DNA strands; MtT, and MtC:  
one pmol of each oligomeric standards mutant T, and mutant C were included in these analyses 
as positive mutation standard markers (see Table 6 for primer sequences).  A standard 10-6 
mixture of genomic DNA from the SW480 cell line provided verification of the detection 
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Figure 6.  Representative autoradiograph of Human KRAS codon 12 site 1 (specimen S03-050). 
LCR blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of 
DNA per specimen; 2x10-6:  3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-
5:  0.3µg of DNA per specimen. Wt:  LCR products from Wild–type DNA strands (see Table 6 
for primer sequences).  A standard 10-6 mixture of genomic DNA from the A549 cell line 
provided verification of the detection sensitivity of the mutant A standard.  Film was exposed for 









Table 7.  Frequency and prevalence of rare single base mutations in human sperm. a
 
TP53 c248s1b TP53 c273s1 TP53 c273s2 KRAS c12s1 
Specimen 
   Prev base     Prev base     Prev base     Prev base 
S00-026  1.0E-6 T  Wt  Wt  1.0E-6 A 
S01-010      Wt Wt Wt Wt
S02-054        1.0E-5 T Wt Wt Wt
S02-063      Wt Wt Wt Wt
S02-365  1.0E-5 T  Wt  Wt  1.0E-6 A 
S03-050     Wt Wt Wt  1.0E-5 A
S03-241  1.0E-5 T  Wt  1.0E-6 A  Wt 
S03-398      Wt Wt Wt Wt
S03-401  1.0E-5 T  Wt  Wt  1.0E-5 A 
S03-402      Wt Wt  1.0E-6 A Wt
S03-428  1.0E-5 T  Wt  1.0E-6 A  Wt 
         
 
a Prevalence is denoted as mutations per 106 genomes, which is equivalent to mutations per 106 sperm. 
b Base sites are denoted by gene, codon (c), and first (s1) or second (s2) base in codon.   
Wt: wild type codon. 







Table 8.  Comparison of frequencies of rare single base mutations sperm and normal somatic cells. 
  Sperm Circulating
Leukocytes
 Normal skin, no 




























0.18/      /0.11 
Prevalenced >1 mt / 106  wt 
genomes 
  ~ 0.7 mt / 106 wt 
genomes 
 
Mean±sd 6±5 mt / 106 wt 
genomes 
  5±1 mt / 106 wt 
genomes 
0.34 
Maximum 20 mt  / 106 wt 
genomes 
  21 mt / 106 wt 
genomes 
 
Median 5 mt / 106 wt 
genomes 
  1 mt / 106 wt 
genomes 
0.10 













































TP53 c248 & c273 9/33 (27%)  2/24 (8%) 9/52 (17%) 0.15/0.54 
TP53 c248 f 6/11 (55%) 5/18 (28%) 2/15 (13%) 4/18 (22%) 0.30/0.07 /0.17 
C742T 6/11 (55%) 4/18 (22%) 2/8 (25%) 4/18 (22%) 0.17/0.41/0.17 
TP53 c273 g 3/22 (14%)  0/9 5/34 (15%) 0.62/0.78 


















Bold:  significant difference at P<0.05. Italics weak significance P< 0.1.  bp: base pair.  mt: mutant cells. NS: not significant.   
sd: standard deviation.  Wt: wild type cells.   
a summary of data reported by Wilson et al.((Wilson et al. 2000)). 
b summary of data reported by Tapp et al.((Tapp et al. 2007)) 
c comparisons between groups - sperm vs. circulating leukocytes (PBL) / sperm vs. normal skin, no cancer / sperm vs. Normal skin 
with adjacent cancer.  Statistical analyses is based on Chi squared analyses with the Yates’ Correction where needed. 









        2/17 (12%) 
2/17 (12%) 
       0.28/0.59 
0.67 
C→T 6/22 (27%) 4/18 (22%) 2/8 (25%) 5/35 (14%) 1.0/0.73/0.39 
G→A 7/22 (32%) 1/48 (2%) 2/37 (5%) 12/53 (23%) 0.001/0.02/0.81 
G→C 0/22      0/53 0/37 2/53 (4%) 0.89
G→T 0/22 11/48 (23%) 1/37 (3%) 1/53 (2%) 0.04/0.79/0.65 
somatic cells.   
e KRAS c12, G34C and G35C or T mutations were not detected.   
f TP53 c248, C742A or G mutations were not detected.   
g TP53 c273, C817A or G and G818T mutations were not detected. 
h Reprinted by permission of John Wiley & Sons, Inc. 
Transition mutations have been reported in CpG sites in other tissues and in SBS 
diseases, such as peripheral blood leukocytes (PBL), normal skin, achondroplasia, and 
vulvar lichen sclerosus (Wilson et al., 2000; Tiemann-Boege et al., 2002; Tapp et al., 
2007).  The precise mechanism and the reason(s) for this apparent bias are unknown at 
this time.  In somatic tissues, oxidative damage has been suggested as a mechanism for 
the production of transition mutations, but the absence of actively inflamed mucosa 
and/or absorption of UV radiation severely limit these as causal factors of mutations in 
sperm.  There is a remote possibility that UV radiation may play a role in the 
development of some oxidative damage during spermatogenesis, which further 
demonstrates the need for more empirical data in this area.  Interestingly, previous reports 
utilizing semen specimens observed only transition mutations at a CpG dinucleotide site, 
which as mentioned above are susceptible to spontaneous deamination (Tiemann-Boege 
et al., 2002).   
3.3  Mutational Frequencies and Prevalence 
Drost and Lee, 1995 proposed that the enzymes involved in repair and control of 
replication fidelity operate at activities within the germ cells which would deliver null 
mutation rates at the gene level between ~10-5 to 10-6 per generation.  The background 
frequency of mutations found herein were in the range of 1 x 10-6 to 2 x 10-5 mutant 
sperm per total spermatozoa sampled for both TP53 and KRAS genes, which are similar 
to previous observations of the frequency of SBS mutations of the FGFR2 and FGFR3 
genes in human sperm (Tiemann-Boege et al., 2002 and Glaser et al., 2003) (Table 2).  
Interestingly, the prevalence/ frequency reported by Tiemann-Boege et al., 2002 and 




but the present study demonstrates a consistent mutational load of normal human sperm, 
which suggest a more general occurrence of these frequencies in normal semen 
specimens.  In this study, 73% (8/11) of the semen specimens contained detectable 
mutants in the five base sites tested (Table 8).  This mutation frequency is higher than 
that observed in PBL (8/19, 42%), PBL (8/19, 42%), normal skin (5/13, 38%), and 
adjacent normal vulvar skin (14/22, 64%), although the base sites studied vary in the PBL 
analyses (Table 8).  Interestingly, these results suggest that a percentage of normal 
individuals may be reservoirs of a significant frequency of oncogenic mutations. 
 The prevalence and frequency of SBS mutations in the KRAS and TP53 genes 
observed in this study are unique; this work represents the first report of SBS frequencies 
of TP53 and KRAS gene mutations in normal human semen specimens.  KRAS gene 
mutations were present in normal semen specimens at a frequency that would not be 
expected from the lack of incidence of genetic disease that would result from the 
constitutional inheritance of these mutations.  In fact, oncogenically activating codon 12 
mutations have not been reported at the constitutional level in any human.  Results of this 
study compared with previous studies (Table 8) suggest that oncogenic mutations are 
present in both sperm and somatic tissues at similar frequencies.  The presence of rare 
oncogenic mutations in somatic disease may lead to cancer, while the presence of sperm 
harboring these same gene mutations has the potential to give rise to individuals 
harboring this error constitutionally.  Fortunately, human constitutional KRAS codon 12 
mutations have not been found and carriers of TP53 mutations, i.e. Li-Fraumeni cancer 
family syndrome carriers, are rare (Olivier et al., 2003; Wu et al., 2006).  This contrast 




genes suggests that selection against these types of mutations must be in fertilization, 
early cleavage, or embryogenesis. Again, based on the incidence of disease in the 
population, selection seems to be more negatively biased against KRAS than TP53 gene 
mutations.  Selection biased against particular mutations in sperm has been reported for 
Apert syndrome.  Two different mutations in the fibroblast growth factor receptor 2 
(FGFR 2) gene codon 755 C >G and codon 758 C >G, can result in Apert syndrome with 
a higher incidence of Apert seen with the codon 755 mutation (Glaser et al., 2003).    
Directly assaying sperm as demonstrated in this study has the potential to answer 
questions that have lingered for decades, such as the impacts of paternal age (Drost & 
Lee, 1995; Crow, 1993; 1996; 2000; Wyrobek et al., 2006), and gonadal mosaicism 
(Selby, 1998) on hereditary risk estimation, origin of hereditary diseases, and evolution. 
A more precise understanding of the different mechanisms governing which mutations 

























 The direct analysis of semen specimens presented in this study provides new 
insight into the prevalence and heritability of mutations in the human germline.  
Interestingly, in these specimens both TP53 and KRAS genes contained frequencies of 
only transitional mutations.  The cause of this bias observed within the mutational 
spectrum is unknown and awaits further investigation.  This is the first study to report 
SBS mutations and frequencies in TP53 and Kristen-Ras codon 12 gene in normal human 
sperm.  The KRAS gene is frequently mutated in somatic disease (i.e. cancers), but a lack 
of reports of constitutional KRAS codons 12,13 or 61 mutations suggest that this 
particular mutation is selected against during the processes of fertilization, early 
cleavage, or embryogenesis.   
The direct examination of sperm has potential applications in diagnostics and 
assessment of disease, such as development of improved risk evaluation, clinical 
treatment protocols, and genetic counseling.  Development of assays and protocols to 
directly evaluate SBS mutations in sperm, in addition to the standard testing of specimens 
such as blood and stool, could lead to higher levels of holistic safety in industries where 
workers are continually exposed to environmental mutagenic hazards.  Treatment 
protocols are increasingly being tailored to individual needs based on available data.  As 
mentioned above, semen specimens can be added to the collection of information 
gathered about the individual, which could address concerns regarding gamete mosaicism 
especially for specific disease causing mutations, and the risks to future offspring 




genetic counseling would benefit from the ability to establish baselines in an individual’s 
semen and monitor changes during intervals of time to improve risk assessment given to 
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